Sub-Q Bionics

Executive Summary

Sub‑Q Bionics is developing an implantable bionic pump to continuously manage lymphatic fluid in cancer-related lymphedema, addressing a significant unmet need in women’s health. The device aims to replace burdensome daily compression therapy, reducing pain, swelling, and infection risk while improving patient mobility. Currently in preclinical stage, the company has raised $1.5 million and is based in Tel Aviv, Israel. Given the large patient population (breast and gynecologic oncology) and the limitations of existing therapies, Sub‑Q’s solution offers a transformative, automated approach to lymphedema management. However, as a preclinical startup, significant technical, regulatory, and commercial hurdles remain. The company’s success hinges on securing additional funding, completing animal studies, and initiating first-in-human trials.

Upcoming Catalysts (preview)

• Q4 2026Series A Financing Round60% success
• Q2 2026Completion of Preclinical Animal Studies70% success
• Q1 2027First-in-Human Clinical Trial Initiation40% success